Recon: Bluebird’s gene therapy eliminates blood transfusions for some beta-thalassemia patients – Regulatory Focus
Regulatory Focus |
Recon: Bluebird's gene therapy eliminates blood transfusions for some beta-thalassemia patients
Regulatory Focus … AI pharma start-up BenevolentAI now worth $2 billion after $115 million funding boost (CNBC) (TechCrunch) (Reuters) (Business Insider) (Endpoints); Kleiner Perkins' Beth Seidenberg bumps Tmunity's cell therapy round to $135M (Endpoints) (Fierce … |
